J&J Settles Risperdal-Related Consumer Fraud Claims With 36 States, DC for $181 Million

Drug Industry Daily
Johnson & Johnson (J&J) has agreed to pay $181 million and enter into a consent decree with 36 states and the District of Columbia to settle allegations that its Janssen subsidiary marketed prescription antipsychotic Risperdal off-label in violation of consumer protection laws, J&J says.

To View This Article:


Subscribe To Drug Industry Daily